360 Network | THE GUIDE | February 1, 2009

Late recurrence, high-risk features, and treatment failure can signal midlife night sweats aren’t menopause, according to Cheryl Cox Kinney, MD.

Hormone therapy was associated with more frequent, longer migraines in postmenopausal women, but not with greater severity or analgesic use.

JoAnn V. Pinkerton, MD, offers primary care counseling on elinzanetant's side effects and the early onset and continued relief of hot flashes.

Menopausal brain fog is common, and hormone therapy has neutral cognitive effects, according to Pauline M. Maki, PhD.

Stephanie S. Faubion, MD, on choosing between fezolinetant and elinzanetant, liver monitoring, follow-up, and open questions in menopause care.

NK receptor antagonists significantly improved sleep disturbance in menopausal women at 4, 12, and 24 weeks in a meta-analysis of RCTs.

Perimenopausal women who were more physically active had significantly lower symptom burden across all domains, a study of 1808 Flo app users found.

JoAnn V. Pinkerton, MD, MSCP, reviews 4 pooled elinzanetant analyses from OASIS presented at The Menopause Society Annual Meeting 2026, spanning late perimenopause, sleep, VMS reduction, and safety.